医学と薬学 78/3 2021年3月号

出版社: 自然科学社
発行日: 2021-02-27
分野: 薬学  >  雑誌
ISSN: 03893898
雑誌名:
特集: 敗血症―再考,そして未来へ(II)
電子書籍版: 2021-02-27 (第1版第1刷)
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安:8~14営業日

2,200 円(税込)

電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

1,540 円(税込)

目次

  • 特集 敗血症―再考,そして未来へ(II)

    敗血症の治療
    敗血症の診断マーカー
    敗血症とARDS
    敗血症と腎障害
    敗血症とDIC
    敗血症と多臓器不全

    薬理・薬剤
     アセトアミノフェンおよびグリシンのブルーライト誘発眼精疲労モデルに対する効果

    研究
     一般生活者を対象とした緑内障治療薬選択とアドヒアランスに関するアンケート調査

    症例報告
     オキサリプラチンにより眼瞼下垂が生じた1 例

    Diagnosis
     全自動化学発光免疫測定装置CL-JACK NX専用試薬CL SP-D「ヤマサ」NXの基礎的検討
     間質性肺炎マーカー測定試薬「Maxpia lp KL-6試薬」の基本性能評価
     コバス PCR メディアの使用によるSARS-CoV-2不活化の検討
     全自動免疫生化学統合システムVITROSによるSARS-CoV-2 IgG抗体測定の基礎的検討
     3種類のCBA法による抗MOG抗体測定の比較検討

    Cosmetic
     スキンケア化粧品“LVリンクルホワイト”の4週間連続使用が加齢肌に与える影響
    「HOTARU PERSONALIZED」を使用したアンチエイジング効果:シミ,シワ,保湿の評価

おすすめ商品

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

【特集 敗血症 - 再考, そして未来へ ( II ) 】

P.211 掲載の参考文献
1) Singer M, Deutschman CS, Seymour CW, et al : The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 315 (8) : 801-810, 2016.
2) Rhodes A, Evans LE, Alhazzani W, et al : Surviving Sepsis Campaign : International Guidelines for Management of Sepsis and Septic Shock : 2016. Crit Care Med 45 (3) : 486-552, 2017.
3) 西田修, 小倉裕司, 井上茂亮, 他 : 日本版敗血症診療ガイドライン 2016. 日救急医会誌 28 (Suppl 1) : S1-232, 2017.
4) 江木盛時, 小倉裕司, 矢田部智昭, 他 : 日本版 敗血症診療ガイドライン 2020 オンライン早期公開版. doi : 10.1002/jja2.S0024.
5) Rudd KE, Johnson SC, Agesa KM, et al : Global, regional, and national sepsis incidence and mortality, 1990-2017 : analysis for the Global Burden of Disease Study. Lancet 395 (10219) : 200-211, 2020.
6) 厚生労働省 : 平成29年患者調査 (傷病分類編) 傷病別年次推移表 敗血症. https://www.mhlw.go.jp/toukei/saikin/hw/kanja/10syoubyo/dl/h29syobyo.pdf (2020年12月22日閲覧)
7) Tulloch LG, Chan JD, Carlbom DJ, et al : Epidemiology and Microbiology of Sepsis Syndromes in a University-Affiliated Urban Teaching Hospital and Level-1 Trauma and Burn Center. J Intensive Care Med 32 (4) : 264-272, 2017.
8) Kaukonen KM, Bailey M, Suzuki S, et al : Mortality related to severe sepsis and septic shock among critically ill patients in Australia and New Zealand, 2000-2012. JAMA 311 (13) : 1308-1316, 2014.
9) Vincent JL, Jones G, David S, et al : Frequency and mortality of septic shock in Europe and North America : a systematic review and meta-analysis. Crit Care 23 (1) : 196, 2019.
10) Levy MM, Evans LE, Rhodes A : The Surviving Sepsis Campaign Bundle : 2018 update. Intensive Care Med 44 (6) : 925-928, 2018.
11) Seymour CW, L iu VX, I washyna TJ, et al : Assessment of Clinical Criteria for Sepsis : For the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 315 (8) : 762-774, 2016.
12) Redfern OC, Smith GB, Prytherch DR, et al : A Comparison of the Quick Sequential (Sepsis-Related) Organ Failure Assessment Score and the National Early Warning Score in Non-ICU Patients With/Without Infection. Crit Care Med 46 (12) : 1923-1933, 2018.
13) Ferrer R, Martin-Loeches I, Phillips G, et al : Empiric antibiotic treatment reduces mortality in severe sepsis and septic shock from the first hour : results from a guideline-based performance improvement program. Crit Care Med 42 (8) : 1749-1755, 2014.
14) Pruinelli L, Westra BL, Yadav P, et al : Delay Within the 3-Hour Surviving Sepsis Campaign Guideline on Mortality for Patients with Severe Sepsis and Septic Shock. Crit Care Med 46 (4) : 500-505, 2018.
15) American College of Emergency Physicians : ACEP Statement on SSC Hour-1 Bundle. https://www.acep.org/by-medical-focus/sepsis/ (2020年12月22日閲覧)
16) Filbin MR, Thorsen JE, Zachary TM, et al : Antibiotic Delays and Feasibility of a 1-Hour-From-Triage Antibiotic Requirement : Analysis of an Emergency Department Sepsis Quality Improvement Database. Ann Emerg Med 75 (1) : 93-99, 2020.
17) Abdul-Aziz MH, Sulaiman H, Mat-Nor MB, et al : Beta-Lactam Infusion in Severe Sepsis (BLISS) : a prospective, two-centre, open-labelled randomised controlled trial of continuous versus intermittent beta-lactam infusion in critically ill patients with severe sepsis. Intensive Care Med 42 (10) : 1535-1545, 2016.
18) Zhao HY, Gu J, Lyu J, et al : Pharmacokinetic and Pharmacodynamic Efficacies of Continuous versus Intermittent Administration of Meropenem in Patients with Severe Sepsis and Septic Shock : A Prospective Randomized Pilot Study. Chin Med J (Engl) 130 (10) : 1139-1145, 2017.
19) Leone M, Bechis C, Baumstarck K, et al : De-escalation versus continuation of empirical antimicrobial treatment in severe sepsis : a multicenter non-blinded randomized noninferiority trial. Intensive Care Med 40 (10) : 1399-1408, 2014.
20) Shehabi Y, Sterba M, Garrett PM, et al : Procalcitonin algorithm in critically ill adults with undifferentiated infection or suspected sepsis. A randomized controlled trial. Am J Respir Crit Care Med 190 (10) : 1102-1110, 2014.
21) Tigabu BM, Davari M, Kebriaeezadeh A, Mojtahedzadeh M : Fluid volume, fluid balance and patient outcome in severe sepsis and septic shock : A systematic review. J Crit Care 48 : 153-159, 2018.
22) Macdonald SPJ, Keijzers G, Taylor DM, et al : Restricted fluid resuscitation in suspected sepsis associated hypotension (REFRESH) : a pilot randomised controlled trial. Intensive Care Med 44 (12) : 2070-2078, 2018.
23) Permpikul C, Tongyoo S, Viarasilpa T, et al : Early Use of Norepinephrine in Septic Shock Resuscitation (CENSER). A Randomized Trial. Am J Respir Crit Care Med 199 (9) : 1097-1105, 2019.
24) Morelli A, Ertmer C, Westphal M, et al : Effect of heart rate control with esmolol on hemodynamic and clinical outcomes in patients with septic shock : a randomized clinical trial. JAMA 310 (16) : 1683-1691, 2013.
25) Wang Z, Wu Q, Nie X, et al : Combination therapy with milrinone and esmolol for heart protection in patients with severe sepsis : a prospective, randomized trial. Clin Drug Investig 35 (11) : 707-716, 2015.
26) Annane D, Renault A, Brun-Buisson C, et al : Hydrocortisone plus Fludrocortisone for Adults with Septic Shock. N Engl J Med 378 (9) : 809-818, 2018.
27) Darenberg J, Ihendyane N, Sjolin J, et al : Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome : a European randomized, double-blind, placebo-controlled trial. Clin Infect Dis 37 (3) : 333-340, 2003.
28) Linner A, Darenberg J, Sjolin J, et al : Clinical efficacy of polyspecific intravenous immunoglobulin therapy in patients with streptococcal toxic shock syndrome : a comparative observational study. Clin Infect Dis 59 (6) : 851-857, 2014.
P.216 掲載の参考文献
1) 西田修, 小倉裕司, 井上茂亮, 他 : 日本版敗血症診療ガイドライン 2016, 日本集中治療医学会誌 24 : S1-232, 2017.
2) 日本版敗血症診療ガイドライン 2020 (J-SSCG2020).
3) Bone RC, Balk RA, Cerra FB, et al : Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 101 : 1644-1655, 1992.
4) Levy MM, Fink MP, Marshall JC, et al : 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 31 : 1250-1206, 2001.
5) Singer M, Deutschman CS, Seymour CW, et al : The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 315 : 801-810, 2016.
6) Ho KM, Lipman J : An update on C-reactive protein for intensivists. Anaesth Intensive Care 37 : 234-241, 2009.
7) Mandell G, Bennett JE, Dolin R : chapter 47 Temperature Regulation of Fever : Acute Phase Responses. Principle and Practice of Infectious Disease 6th edition, pp.709-712, Churchill Livingstone, London, 2005.
8) Lelubre C, Anselin S, Boudjeltia KZ, et al : Interpretation of C-reactive protein concentrations in critically ill patients. Biomed Res Int 2013 : 124021, 2013.
9) Heinrich PC, Castell JV : Andus T Interleukin-6 and the acute phase response. Biochem J 265 : 621-636, 1990.
10) Hirano T, Yasukawa K, Harada H, et al : Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature 324 : 73-76, 1986.
11) Oda S, Hirasawa H, Shiga H, et al : Sequential measurement of il-6 blood levels in patient with systemic inflammatory response syndrome sepsis. Cytokine 29 : 169-175, 2005.
12) Becker KL, Snider R, Nylen ES : Procalcitonin assay in systemic inflammation, infection, and sepsis : Clinical utility and limitations. Crit Care Med 36 : 941-952, 2008.
13) Dandona P, Nix D, Wilson WF : Procalcitonin increase after endotoxin injection in normal subjects. J Clin Endocrinol Metab 79 : 1605-1608, 1994.
14) Meisner M, Tschaikowsky K, Palmaers T, et al : Comparison of procalcitonin (PCT) and C-reactive protein (CRP) plasma concentrations at different SOFA scores during the course of sepsis and MODS. Crit Care 3 : 45-50, 1999.
15) Vijayan AL, Vanimaya, Ravindran S, et al : Procalcitonin : a promising diagnostic marker for sepsis and antibiotic therapy. J Intensive Care 5 : 51, 2017.
16) Bloos F, Trips E, Nierhaus A, et al : Effect of Sodium Selenite Administration and Procalcitonin-Guided Therapy on Mortality in Patients with Severe Sepsis or Septic Shock : A Randomized Clinical Trial. JAMA Intern Med 176 : 1266-1276, 2016.
17) Kim H, Hur M, Moon HW, et al : Multi-marker approach using procalcitonin, presepsin, galectin-3, and soluble suppression of tumorigenicity 2 for the prediction of mortality in sepsis. Ann Intensive Care 7 : 27, 2017.
18) 三鴨廣繁, 山岸由佳, 他 : 感染症診療における新しいバイオマーカー「プレセプシン」. 感染症誌 88 : 520-521, 2014.
19) Godnic M, Stubljar D, Skvarc M, et al : Diagnostic and prognostic value of sCD14-ST-presepsin for patients admitted to hospital intensive care unit (ICU). Wien Klin Wochenschr 127 : 521-527, 2015.
20) Kim H, Hur M, Moon HW, et al : Multi-marker approach using procalcitonin, presepsin, galectin-3, and soluble suppression of tumorigenicity 2 for the prediction of mortality in sepsis. Ann Intensive Care 7 : 27, 2017
21) Ulla M, Pizzolato E, Lucchiari M, et al : Diagnostic and prognostic value of presepsin in the management of sepsis in the emergency department : a multicenter prospective study. Crit Care 17 : R168, 2013.
22) Kondo Y, Umemura Y, Hayashida K, et al : Diagnostic value of procalcitonin and presepsin for sepsis in critically ill adult patients : a systematic review and meta-analysis. J Intensive Care 7 : 22, 2019.
23) Takahashi W, Nakada TA, Yazaki M, et al : Interleukin-6 Levels Act as a Diagnostic Marker for Infection and a Prognostic Marker in Patients with Organ Dysfunction in Intensive Care Units. Shock 46 : 254-260, 2016.
24) Ishikura H, Nishida T, Murai A, et al : New diagnostic strategy for sepsis-induced disseminated intravascular coagulation : a prospective single-center observational study. Critical Care 18 : R19, 2014.
25) Shozushima T, Takahashi G, Matsumoto N, et al : Usefulness of presepsin (sCD14-ST) measurements as a marker for the diagnosis and severity of sepsis that satisfied diagnostic criteria of systemic inflammatory response syndrome. J Infect Chemother 17 : 764-769, 2011.
26) Tang BM, Eslick GD, Craig JC, et al : Accuracy of procalcitonin for sepsis diagnosis in critically ill patients : systematic review and meta-analysis. Lancet Infect Dis 7 : 210-217, 2007.
27) Sakran JV, Michetti CP, Sheridan MJ, et al : The utility of procalcitonin in critically ill trauma patients. J Trauma Acute Care Surg 73 : 413-418, 2012
28) Seoane L, Pertega S, Galeiras R, et al : Procalcitonin in the burn unit and the diagnosis of infection. Burns 40 : 223-229, 2014.
29) Becker KL, Snider R, Nylen ES : Procalcitonin assay in systemic inflammation, infection, and sepsis : Clinical utility and limitations. Crit Care Med 36 : 941-952, 2008.
30) Nakamura Y, Ishikura H, Nishida T, et al : Usefulness of presepsin in the diagnosis of sepsis in patients with or without acute kidney injury. BMC Anesthesiol 14 : 88, 2014.
31) Urbonas V, Eidukaite A, Tamuliene I : The predictive value of soluble biomarkers (CD14 subtype, interleukin-2 receptor, human leucocyte antigen-G) and procalcitonin in the detection of bacteremia and sepsis in pediatric oncology patients with chemotherapy-induced febrile neutropenia. Cytokine 62 : 34-37, 2013.
P.223 掲載の参考文献
2) Bernard GR, Artigas A, Brigham KL, et al : Report of the American-European Consensus conference on acute respiratory distress syndrome : definitions, mechanisms, relevant outcomes, and clinical trial coordination. Consensus Committee, J Crit Care 9 : 72-81, 1994.
3) ARDS Definition Task Force, Ranieri VM, Rubenfeld GD, Thompson BT, et al : Acute respiratory distress syndrome : the Berlin Definition. JAMA 307 : 2526-2533, 2012.
4) Singer M, Deutschman CS, Seymour CW, et al : The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 315 : 801-810, 2016.
5) Abe T, Ogura H, Shiraishi A, et al : Characteristics, management, and in-hospital mortality among patients with severe sepsis in intensive care units in Japan : the FORECAST study. Crit Care 22 : 322, 2018.
6) Iriyama H, Abe T, Kushimoto S, et al : Risk modifiers of acute respiratory distress syndrome in patients with non-pulmonary sepsis : a retrospective analysis of the FORECAST study. J Intensive Care 8 : 7, 2020.
7) Bellani G, Laffey JG, Pham T, et al : Epidemiology, Patterns of Care, and Mortality for Patients With Acute Respiratory Distress Syndrome in Intensive Care Units in 50 Countries. JAMA 315 : 788-800, 2016.
8) Herridge MS, Cheung AM, Tansey CM, et al : One-year outcomes in survivors of the acute respiratory distress syndrome. N Engl J Med 348 : 683-693, 2003.
10) Kapfhammer HP, Rothenhausler HB, Krauseneck T, et al : Posttraumatic stress disorder and health-related quality of life in long-term survivors of acute respiratory distress syndrome. Am J Psychiatry 161 : 45-52, 2004.
12) 一般社団法人日本集中治療医学会/一般社団法人日本呼吸療法医学会, ARDS診療ガイドライン作成委員会 : 委員会報告 ARDS診療ガイドライン 2016. 日集中医誌 24 : 57-63, 2017.
13) Hogg JC, Doerschuk CM : Leukocyte traffic in the lung. Annu Rev Physiol 57 : 97-114,1995.
14) ARDS診療ガイドライン2016作成委員会編 : ARDS診療ガイドライン 2016, 2016
15) Bernard GR, Luce JM, Sprung CL, et al : Highdose corticosteroids in patients with the adult respiratory distress syndrome. N Engl J Med 317 : 1565-1570, 1987.
16) Tongyoo S, Permpikul C, Mongkolpun W, et al : Hydrocortisone treatment in early sepsis-associated acute respiratory distress syndrome : results of a randomized controlled trial. Crit Care 20 : 329, 2016.
17) Meduri GU, Headley AS, Golden E, et al : Effect of prolonged methylprednisolone therapy in unresolving acute respiratory distress syndrome : a randomized controlled trial. JAMA 280 : 159-165, 1998.
18) Meduri GU, Golden E, Freire AX, et al : Methylprednisolone infusion in early severe ARDS : results of a randomized controlled trial. Chest 131 : 954-963, 2007.
19) Steinberg KP, Hudson LD, Goodman RB, et al : Efficacy and safety of corticosteroids for persistent acute respiratory distress syndrome. N Engl J Med 354 : 1671-1684, 2006.
20) Villar J, Ferrando C, Martinez D, et al : Dexamethasone treatment for the acute respiratory distress syndrome : a multicentre, randomised controlled trial. Lancet Respir Med 8 : 267-276, 2020.
21) 玉熊正悦, 柴忠明, 平澤博之, 他 : 好中球エラスターゼ阻害剤 ; ONO-5046・Naの全身性炎症反応症候群に伴う肺障害に対する有効性と安全性の検討-前期第III相二重盲検比較試験-. 臨床医薬 14 : 289-318, 1998.
23) Munshi L, Del Sorbo L, Adhikari NKJ, et al : Prone Position for Acute Respiratory Distress Syndrome. A Systematic Review and Meta-Analysis. Ann Am Thorac Soc 14 : S280-288, 2017.
24) Famous KR, Delucchi K, Ware LB, et al : Acute Respiratory Distress Syndrome Subphenotypes Respond Differently to Randomized Fluid Management Strategy. Am J Respir Crit Care Med 195 : 331-338, 2017.
P.228 掲載の参考文献
1) Singer M, Deutschman CS, Seymour CW, et al : The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 315 : 801-810, 2016.
2) KDIGO AKI Working Group. KDIGO clinical practice guideline for acute kidney injury. Kidney Int 2 (Suppl 1), 2012.
3) Kotani Y, Fujii T, Uchino S, et al : Modification of sequential organ failure assessment score using acute kidney injury classification. J Crit Care 51 : 198-203, 2019.
4) Uchino S, Kellum JA, Bellomo R, et al : Beginning and Ending Supportive Therapy for the Kidney (BEST Kidney) Investigators. Acute renal failure in critically ill patients : a multinational, multicenter study. JAMA 294 : 813-818, 2005.
5) Miyamoto Y, Iwagami M, Aso S, et al : Temporal change in characteristics and outcomes of acute kidney injury on renal replacement therapy in intensive care units : analysis of a nationwide administrative database in Japan, 2007-2016. Crit Care 23 : 172, 2019.
6) Wald R, McArthur E, Adhikari NK, et al : Changing incidence and outcomes following dialysis-requiring acute kidney injury among critically ill adults : a population-based cohort study. Am J Kidney Dis 65 : 870-877, 2015.
7) Carlson N, Hommel K, Olesen JB, et al : Trends in One-Year Outcomes of Dialysis-Requiring Acute Kidney Injury in Denmark 2005-2012 : A Population-Based Nationwide Study. PLoS One 11 : e0159944, 2016.
8) Gaudry S, Hajage D, Schortgen F, et al : Initiation Strategies for Renal-Replacement Therapy in the Intensive Care Unit. N Engl J Med 375 : 122-133.
9) Zarbock A, Kellum JA, Schmidt C, et al : Effect of Early vs Delayed Initiation of Renal Replacement Therapy on Mortality in Critically Ill Patients With Acute Kidney Injury : The ELAIN Randomized Clinical Trial. JAMA 315 : 2190-2199, 2016.
10) Barbar SD, Clere-Jehl R, Bourredjem A, et al : Timing of Renal-Replacement Therapy in Patients with Acute Kidney Injury and Sepsis. N Engl J Med 379 : 1431-1442, 2018.
11) STARRT-AKI Investigators; Canadian Critical Care Trials Group; Australian and New Zealand Intensive Care Society Clinical Trials Group ; United Kingdom Critical Care Research Group ; Canadian Nephrology Trials Network ; Irish Critical Care Trials Group, Bagshaw SM, Wald R, Adhikari NKJ, et al : Timing of Initiation of Renal-Replacement Therapy in Acute Kidney Injury. N Engl J Med 383 (3) : 240-251, 2020.
12) Ostermann M, Zarbock A, Goldstein S, et al : Recommendations on Acute Kidney Injury Biomarkers From the Acute Disease Quality Initiative Consensus Conference : A Consensus Statement. JAMA Netw Open 3 (10) : e2019209, 2020.
13) AKI (急性腎障害) 診療ガイドライン作成委員会編 : AKI (急性腎障害) 診療ガイドライン 2016. 日腎会誌 59 : 419-533, 2017.
14) Khanna A, English SW, Wang XS, et al : ATHOS-3 Investigators. Angiotensin II for the Treatment of Vasodilatory Shock. N Engl J Med 377 (5) : 419-430, 2017.
15) Tumlin JA, Murugan R, Deane AM, et al : Angiotensin II for the Treatment of High-Output Shock 3 (ATHOS-3) Investigators. Outcomes in Patients with Vasodilatory Shock and Renal Replacement Therapy Treated with Intravenous Angiotensin II. Crit Care Med 46 (6) : 949-957, 2018.
16) Mari n-Grez M, Fleming JT, Steinhausen M : Atrial natriuretic peptide causes pre-glomerular vasodilatation and post-glomerular vasoconstriction in rat kidney. Nature 324 (6096) : 473-476, 1986.
17) Pickkers P, Mehta RL, Murray PT, et al, STOPAKI Investigators : Effect of Human Recombinant Alkaline Phosphatase on 7-Day Creatinine Clearance in Patients With Sepsis-Associated Acute Kidney Injury : A Randomized Clinical Trial. JAMA 320 : 1998-2009, 2018.
P.234 掲載の参考文献
1) Singer M, Deutschman CS, Seymour CW, et al : The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 315 (8) : 801-810, 2016.
2) Ito T : PAMPs and DAMPs as triggers for DIC. J Intensive Care 2 (1) : 67, 2014.
3) Massberg S, Grahl L, von Bruehl ML, et al : Reciprocal coupling of coagulation and innate immunity via neutrophil serine proteases. Nat Med 16 (8) : 887-896, 2010.
4) Engelmann B, Massberg S : Thrombosis as an intravascular effector of innate immunity. Nat Rev Immunol 13 (1) : 34-45, 2013.
5) Kerschen E, Hernandez I, Zogg M, et al : Survival advantage of heterozygous factor V Leiden carriers in murine sepsis. J Thromb Haemost 13 (6) : 1073-1080, 2015.
6) Umemura Y, Yamakawa K : Optimal patient selection for anticoagulant therapy in sepsis : an evidence-based proposal from Japan. J Thromb Haemost 16 (3) : 462-464, 2018.
7) 日本版敗血症診療ガイドライン 2020 (J-SSCG 2020).
8) Warren BL, Eid A, Singer P, et al : Caring for the critically ill patient. High-dose antithrombin III in severe sepsis : a randomized controlled trial. JAMA 286 (15) : 1869-1878, 2001.
9) Kienast J, Juers M, Wiedermann CJ, et al : Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. J Thromb Haemost 4 (1) : 90-97, 2006.
10) Ito T, Thachil J, Asakura H, et al : Thrombomodulin in disseminated intravascular coagulation and other critical conditions-a multi-faceted anticoagulant protein with therapeutic potential. Crit Care 23 (1) : 280, 2019.
11) Ito T, Maruyama I, Shimazaki S, et al : Effects of thrombomodulin alfa on hemostatic parameters in disseminated intravascular coagulation : Post hoc analysis of a phase 3 randomized controlled trial. Res Pract Thromb Haemost 4 (7) : 1141-1149, 2020.
12) Vincent JL, Ramesh MK, Ernest D, et al : A randomized, double-blind, placebo-controlled, Phase 2b study to evaluate the safety and efficacy of recombinant human soluble thrombomodulin, ART-123, in patients with sepsis and suspected disseminated intravascular coagulation. Crit Care Med 41 (9) : 2069-2079, 2013.
13) Vincent JL, Francois B, Zabolotskikh I, et al : Effect of a Recombinant Human Soluble Thrombomodulin on Mortality in Patients With Sepsis-Associated Coagulopathy : The SCARLET Randomized Clinical Trial. JAMA 321 (20) : 1993-2002, 2019.
14) Yamakawa K, Levy JH, Iba T : Recombinant human soluble thrombomodulin in patients with sepsis-associated coagulopathy (SCARLET) : an updated meta-analysis. Critical care 23 (1) : 302, 2019.
15) Valeriani E, Squizzato A, Gallo A, et al : Efficacy and safety of recombinant human soluble thrombomodulin in patients with sepsis-associated coagulopathy : A systematic review and meta-analysis. J Thromb Haemost 18 (7) : 1618-25, 2020.
P.241 掲載の参考文献
1) Singer M, Deutschman CS, Seymour CW, et al : The third international consensus definitions for sepsis and septic shock (sepsis-3). JAMA 315 : 801-810, 2016.
2) Members of the American College of Chest Physicians/Society of Critical Medicine Consensus Conference Committee : Difinitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest 101 : 1644-1655, 1992.
3) Cinel I, Opal SM : Molecular biology of inflammation and sepsis : a primer. Crit Care Med 37 : 291-304, 2009.
4) 平澤博之 : Severe Sepsis/Septic shockの病態生理と急性血液浄化法によるその制御. 日本急性血液浄化学会雑誌 1 (1) : 3-16, 2010.
5) Endo S, Takahashi G, Shozushima T, et al : Usefulness of presepsin (soluble CD14 subtype) as a diagnostic maker for sepsis. JJAAM 23 : 27-38, 2012.
6) 平澤博之 : 私と急性血液浄化法-思いつくままに-. 日本急性血液浄化学会誌 8 : 3-9, 2017.
7) Bellomo R, Ronco C, Kellum JA, et al : Acute dialysis quality initiative workgroup. Acute renal failure. Crit Care 8 : R204-212, 2004.
8) Mehta RL, kellum JA, Shah SV, et al : Acue Kidney Injury Network : report of an initiative to improve outcomes in acute kidney injury. Crit Care 11 : R31, 2007.
9) Jacobsson B, Lignelid H, Bergerheim US : Transthyretin and cystatin C are catabolized in proximal tubulae epithelial cells and the proteins are not useful as maker for renal cell carcinomas. Histopathology 26 : 559-564, 1995.
10) Mishra J, Dent C, Tarabishi R, et al : Neutrophil gelatinase-associated lipocalin (NGAL) as a biomaker for acute renal injury after cardiac surgery. Lancet 365 : 1231-1238, 2005.
11) Nakamura T, Sugaya T, Node K et al : Urinary excretion of liver-type fatty acid-binding protein in contrast medium-induced nephropaty. Am J kidney Dis 47 : 439-444, 2006.
12) 鈴木泰, 佐藤信博, 小鹿雅博ら : 敗血症性多臓器不全に対する血液浄化法. ICUとCCU 33 (2) : 135-140, 2009.
13) Kidney Disease : Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney int Suppl 2 : 1-138, 2012.
14) 丸藤哲, 射場敏明, 江口豊, 他 : 急性期DIC診断基準. 日救急医会誌 16 : 188-202, 2005.
15) Emeis JJ, Kooistra T : Inerleukin 1 and lipopolysaccharide induce an inhibitor of tissue-type plasminogen activator in vivo and in cultured endothelial cells. J Exp Med 163 : 1260-1266, 1986.
16) Katagiri D, Ishikane M, Ogawa T, et al : Continuous renal replacement therapy for a patient with severe COVID-19. Blood Purif 50 (1) : 129-131, 2021
17) 真弓俊彦 : 救急集中治療領域における最新の敗血症治療-surviving sepsis campaign guidelinesとその後の知見-. エンドトキシン血症救命治療研究会誌 14 : 27-34, 2010.

【薬理・薬剤】

P.248 掲載の参考文献
1) 石原忍 : 小眼科学 : 10-11, 1979.
2) 総務省情報通信政策研究所「平成30年度情報通信メディアの利用時間と情報行動に関する調査」報告書
3) 大野志郎 : ネット逃避の現状. 情報通信政策研究 2 (2) : 49-65, 2019.
4) Sheppard AL, Wolffsohn JS : Digital eye strain : prevalence, measurement and amelioration. BMJ Open Ophthalmol 3 : e000146, 2018.
5) Antona B, Barrio AR, Gasco A, et al : Symptoms associated with reading from a smartphone in conditions of light and dark. Appl Ergon 68 : 12-17, 2018.
6) Lin JB, Gerratt BW, Bassi CJ, et al : Short-Wavelength Light-Blocking Eyeglasses Attenuate Symptoms of Eye Fatigue. Invest Ophthalmol Vis Sci 58 (1) : 442-447, 2017.
7) Lin CH, Wu MR, Huang WJ, et al : Low-Luminance Blue Light-Enhanced Phototoxicity in A2E-Laden RPE Cell Cultures and Rats. Int J Mol Sci 20 : 1799, 2019.
8) 菅原岳史 : ERGでみる網膜光障害. 眼科診療プラクティス 眼の光障害 5 (7) : 44-47, 2002.
9) Bernardo-Colon A, Vest V, Clark A, et al : Antioxidants prevent inflammation and preserve the optic projection and visual function in experimental neurotrauma. Cell Death and Dis 9 : 1097, 2018.
10) Maharaj H, Maharaj DS, Daya S : Acetylsalicylic acid and acetaminophen protect against oxidative neurotoxicity. Metab Brain Dis 21 : 189-199, 2006.
11) Tripathy D, Grammas P : Acetaminophen inhibits neuronal inflammation and protects neurons from oxidative stress. J Neuroinflammation 6 : 10, 2009.
12) Tripathy D, Grammas P : Acetaminophen protects brain endothelial cells against oxidative stress. Microvasc Res 77 (3) : 289, 2009.
13) Amin FU, Shah SA, Kim MO : Glycine inhibits ethanol-induced oxidative stress, neuroinflammation and apoptotic neurodegeneration in postnatal rat brain. Neurochem Int 96 : 1-12, 2016.
14) Kawai N, Sakai N, Okuro M, et al : The Sleep-Promoting and Hypothermic Effects of Glycine are Mediated by NMDA Receptors in the Suprachiasmatic Nucleus. Neuropsychopharmacology 40 : 1405-1416, 2015.
15) Haraguchi K, Kawamoto A, Isami K, et al : TRPM2 Contributes to Inflammatory and Neuropathic Pain through the Aggravation of Pronociceptive Inflammatory Responses in Mice. J Neurosci 32 (11) : 3931-3941, 2012.
16) Andersson DA, Gentry C, Alenmyr L, et al : TRPA1 mediates spinal antinociception induced by acetaminophen and the cannabinoid Δ (9)-tetrahydrocannabiorcol. Nat Commun 2 : 551, 2011.

【研究】

P.255 掲載の参考文献
1) Collaborative Normal-Tension Glaucoma Study Group. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Am J Ophthalmol 126 : 498-505, 1998.
2) 日本緑内障学会緑内障診療ガイドライン作成委員会. 緑内障診療ガイドライン (第4版). 日眼会誌 122 (1) : 5-53, 2018.
3) European Glaucoma Society. Terminology and guidelines for glaucoma (4th edition). pp.131-138, Publicomm, Savona, Italy, 2014.
4) Tsai JC, McClure CA, Ramos SE, et al : Compliance barrier in glaucoma : a systematic classification. J Glaucoma 12 (5) : 393-398, 2003.
5) Quigley HA, Friedman DS, Hahn SR : Evaluation of practice patterns for the care of open-angle glaucoma compared with claims data : The Glaucoma Adherence and Persistency Study. Ophthalmology 114 (9) : 1599-1606, 2007.
6) 河本光平, 坂口麻理子, 島野卓史, 他. スギ花粉症治療における患者中心の薬剤選択の試み. 耳鼻と臨床 59 (6) : 260-274, 2013.
7) 田中敏博, 近藤美鈴, 淵上あき, 他 : 緑内障患者通院継続支援システム導入による緑内障患者の通院継続率に及ぼす影響. 眼科 62 (9) : 801-807, 2020.
8) Yamada M, Nakano T, Matsuda H, et al : Cost-effectiveness and budget impact analysis of a patient visit support system for blindness reduction in Japanese patients with glaucoma. J Med Econ 23 (11) : 1293-1301, 2020.

【症例報告】

P.259 掲載の参考文献
1) Pasetto LM, D'Andrea MR, Rossi E, et al : Oxaliplatin-related neurotoxicity : how and why? Crit Rev Oncol Hematol 59 (2) : 159-168, 2006.
2) Lau SC, Shibata SI : Blepharoptosis following oxaliplatin administration. J Oncol Pharm Pract 15 (4) : 255-257, 2009.
3) La Verde N, Garassino MC, Spinelli G, et al : Reversible palpebral ptosis following oxaliplatin infusion. Dig Liver Dis 39 (11) : 1041, 2007.
4) Andre T, Boni C, Navarro M, et al : Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC Trial. J Clin Oncol 27 (19) : 3109-3116, 2009.
5) Adelsberger H, Quasthoff S, Grosskreutz J, et al : The chemotherapeutic oxaliplatin alters voltage-gated Na (+) channel kinetics on rat sensory neurons. Eur J Pharmacol 406 (1) : 25-32, 2000.
6) Ta LE, Espeset L, Podratz J, et al : Neurotoxicity of oxaliplatin and cisplatin for dorsal root ganglion neurons correlates with platinum-DNA binding. Neurotoxicology 27 (6) : 992-1002, 2006.
7) Petrioli R, Pascucci A, Francini E, et al : Neurotoxicity of FOLFOX-4 as adjuvant treatment for patients with colon and gastric cancer : a randomized study of two different schedules of oxaliplatin. Cancer Chemother Pharmacol 61 (1) : 105-111, 2008.
8) Leonard GD, Wright MA, Quinn MG, et al : Survey of oxaliplatin-associated neurotoxicity using an interview-based questionnaire in patients with metastatic colorectal cancer. BMC Cancer 16 (5) : 116, 2005.
9) 野口裕介, 川島悠吾, 瓦比呂子, 他 : Oxaliplatinによる眼障害に関する後方視的検討. 癌と化学療法 42 (11) : 1401-1405, 2015.

【Diagnosis】

P.267 掲載の参考文献
1) Takahashi H, Sano H, Chiba H, et al : Pulmonary surfactant proteins A and D : innate immune functions and biomarkers for lung diseases. Curr Pharm Des 12 (5) : 589-598, 2006.
2) Kuroki Y, Takahashi H, Chiba H, et al : Surfactant proteins A and D : disease markers. Biochim Biophys Acta 1408 (2-3) : 334-345, 1998.
3) 高橋弘毅, 白鳥正典, 千葉弘文 : IPFのバイオマーカー 2) SP-D, SP-A. 呼吸器内科 19 (6) : 597-604, 2011.
4) 大屋沙織, 山口雄平, 小野仁, 他 : 全自動化学発光免疫測定装置「CL-JACK NX」を用いた「デタミナーCLレニン」の基本性能. 医療と検査機器・試薬 39 (4) : 391-397, 2016.
5) 田中誠仁, 佐藤高明, 永江尚人, 他 : 肺サーファクタント蛋白質D (SP-D) の短時間測定法SP-Dキット「ヤマサ」EIA IIの開発. 医学と薬学 59 (3) : 439-446, 2008.
6) 村田誠, 宇津貴央, 荒井智, 他 : 全自動化学発光免疫測定装置CL-JACK専用試薬CL SP-D「ヤマサ」の基礎的検討. 医学と薬学 71 (12) : 2303-2308, 2014.
P.274 掲載の参考文献
1) 河野修興 : KL-6. 呼吸 16 : 391-397, 1997.
2) Kohno N, Kyoizumi S, Awaya Y, et al : New serum indicator interstitial pneumonitis activity. CHEST 96 (1) : 63-73, 1989.
3) 近藤圭一, 河野修興 : KL-6抗原. 臨床化学 32 : 234-239, 2003.
4) 錦織昌明, 川中玲子, 坂本祐子, 他 : ラテックス凝集比濁法を用いた生化学自動分析装置日立ラボスペクト008による血中KL-6測定法の基礎的検討. 日赤検査 45 (2) : 17-20, 2012.
5) 河野修興, 日和田邦男, 小林淳, 他 : 電気化学発光免疫測定法によるKL-6測定キットED066の間質性肺炎に対する診断能. 臨床と研究 75 (5) : 217-222, 1998.
P.280 掲載の参考文献
1) 厚生労働省 : 新型コロナウイルス感染症 (COVID-19) 病原体検査の指針 第2版, 2020年11月11日
2) 一般社団法人日本環境感染学会 : 医療機関における新型コロナウイルス感染症への対応ガイド 第3版, 2020年5月8日
3) Ueda, K, Kawabata, R, Sakaguchi, T, et al : Inactivation of pathogenic viruses by plant-derived tannins : strong effects of extracts from persimmon (Diospyros kaki) on a board range of viruses. PLoS One 8 (1) : e55343, 2013.
P.288 掲載の参考文献
1) WHO Director-General's opening remarks at the media briefing on COVID-19-11 March 2020. World Health Organization, home page. 11 March 2020. https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarksat-the-media-briefing-on-covid-1911-march-2020〔2020年12月〕
2) Dong E, Du H, Gardner L, et al : An interactive web-based dashboard to track COVID-19 in real time [manuscript published online ahead of print 19 February 2020] Lancet Infect Dis 2020 COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU). https://www.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6) 2020年12月〕
3) Peng Zhou, Xing-LouYang, XianGuang Wang, et al : A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579 : 270-273, 2020.
4) Huan Ma, Weihong Zeng, Hongliang He, et al : Serum IgA, IgM, and IgG responses in COVID-19. Cellular & Molecular Immunology 17 : 773-775, 2020.
5) Fujigaki H, Takemura M, Osawa M, et al : Reliability of serological tests for COVID-19 : comparison of three immunochromatography test kits for SARS-CoV-2 antibodies. Heliyon 6 : e04929, 2020.
6) Nicol T, Lefeuvre C, Serri O, et al : Assessment of SARS-CoV-2 serological tests for the diagnosis of COVID-19 through the evaluation of three immunoassays : Two automated immunoassays (Euroimmun and Abbott) and one rapid lateral flow immunoassay (NG Biotech). J Clin Virol 129 : 104511, 2020.
7) Summers M, Booth T, Brockas H, et al : Luminogenic reagent using 3-choro 4-hydroxy acetanilide to enhance peroxidase/luminol chemiluminescence. Clin Chem 41 : S73, 1995.
8) Pan Y, Li X, Yang G, et al : Serological immunechromatographic approach in diagnosis with SARS-CoV-2 infected COVID-19 patients. J Infect 81 : 28-32, 2020.
9) Liu W, Liu L, Kou G, et al : Evaluation of Nucleocapsid and Spike Protein-Base Enzyme-Linked Immunosorbent Assays for Detecting Antibodies against SARS-CoV-2. J Clin Microbiol 58 : e00461-20, 2020.
10) Fujigaki H, Inaba M, Osawa M, et al : Comparative analysis of antigen-specific anti-SARS-CoV-2 antibody isotypes in COVID-19 patients. doi : https://doi.org/10.1101/2020.12.04.407510
P.291 掲載の参考文献
1) Di Pauli F, Mader S, Rostasy K, et al : Temporal dynamics of anti-MOG antibodies in CNS demyelinating diseases. Clin Immunol 138 (3) : 247-254, 2011. doi : 10.1016/j.clim.2010.11.013. Epub 2010 Dec 18. PMID : 21169067.
2) Mader S, Gredler V, Schanda K, et al : Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders. J Neuroinflammation 8 : 184, 2011. doi : 10.1186/1742-2094-8-184. PMID : 22204662 ; PMCID : PMC3278385.
3) Jarius S, Paul F, Aktas O, et al : MOG encephalomyelitis : international recommendations on diagnosis and antibody testing. J Neuroinflammation 15 (1) : 134, 2018. doi : 10.1186/s12974-018-1144-2. PMID : 29724224 ; PMCID : PMC5932838.
4) Otto F, Moser T, Feige J, et al : Successful disease control with alemtuzumab in MOG-IgG-associated demyelinating disease with MS-phenotype. Mult Scler Relat Disord 42 : 102108, 2020. doi : 10.1016/j.msard.2020.102108. Epub 2020 Apr 15. PMID : 32339987.
5) Waters PJ, Komorowski L, Woodhall M, et al : A multicenter comparison of MOG-IgG cell-based assays. Neurology 92 (11) : e1250-e1255, 2019. doi : 10.1212/WNL.0000000000007096. Epub 2019 Feb 6. PMID : 30728305 ; PMCID : PMC6511109.
6) Reindl M, Schanda K, Woodhall M, et al : International multicenter examination of MOG antibody assays. Neurol Neuroimmunol Neuroinflamm 7 (2) : e674, 2020. doi : 10.1212/NXI.0000000000000674. Erratum in : Neurol Neuroimmunol Neuroinflamm. 2020 Mar 20 ; 7 (3) : PMID : 32024795 ; PMCID : PMC7051197.
7) Waters P, Woodhall M, O'Connor KC, et al : MOG cell-based assay detects non-MS patients with inflammatory neurologic disease. Neurol Neuroimmunol Neuroinflamm 2 (3) : e89, 2015. doi : 10.1212/NXI.0000000000000089. PMID : 25821844 ; PMCID : PMC4370386.
8) Kim Y, Hyun JW, Woodhall MR, et al : Refining cell-based assay to detect MOG-IgG in patients with central nervous system inflammatory diseases. Mult Scler Relat Disord 40 : 101939, 2020. doi : 10.1016/j.msard.2020.101939. Epub 2020 Jan 9. PMID : 31978673.
9) Gastaldi M, Scaranzin S, Jarius S, et : Cell-based assays for the detection of MOG antibodies : a comparative study. J Neurol 267 (12) : 3555-3564, 2020. doi : 10.1007/s00415-020-10024-0. Epub 2020 Jul 4. PMID : 32623596.
10) Sato DK, Callegaro D, Lana-Peixoto MA, et al : Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology. 82 (6) : 474-481, 2014. doi : 10.1212/WNL.0000000000000101. Epub 2014 Jan 10. PMID : 24415568 ; PMCID : PMC3937859.
11) Ogawa R, Nakashima I, Takahashi T, et al : MOG antibody-positive, benign, unilateral, cerebral cortical encephalitis with epilepsy. Neurol Neuroimmunol Neuroinflamm 4 (2) : e322, 2017. doi : 10.1212/NXI.0000000000000322. PMID : 28105459 ; PMCID : PMC5241006.

【Cosmetic】

P.303 掲載の参考文献
1) 山田秀和 : 最近の女性に多いシワの種類に対する傾向と対策. COSMETIC CTAGE 12 (2) : 1-7, 2017.
2) 山崎律子 : 加齢による皮膚の変化とスキンケア. 繊維製品消費科学 55 (11) : 823-826, 2014.
3) 三浦渚, 村上泉子, 小池都子, 他 : 三次元画像相関法を用いた顔面皮膚表面ひずみ測定 (皮膚に生じるひずみと皮膚性状の関係). 日本機械学会論文集 79 (802) : 774-778, 2013.
4) 濱田一輝, 溝上陽子, 菊地久美子, 他 : 肌画像における肌色の弁別特性. 日本色彩学会誌 42 (2) : 50-58, 2018.
5) 日本香粧品学会編集事務局 : <化粧品機能評価法ガイドライン> 新規効能取得のための医薬部外品美白機能評価試験ガイドライン. 日本香粧品学会誌 30 (4) : 333-337, 2006.
6) 日本香粧品学会編集事務局 :抗シワ製品評価ガイドライン. 日本香粧品学会誌 30 (4) : 316-332. 2006.
7) 柳井久江 : 4 Steps エクセル統計 第4版. オーエムエス出版, 東京, 2015.
8) 日本化粧品工業会 : 化粧品統計 : 化粧品と薬用化粧品. https://www.jcia.org/user/statistics/cosmeceuticals〔最終アクセス2021年1月22日〕
9) 植木拓朗 : 化粧品の使用場面に合わせた品質保証に必要な観点. 安全性評価-原料・商品・発売後-. 日本化粧品技術者会誌 54 (4) : 309-314, 2020.
10) 丹野修 : ビタミン類の新機能と化粧品への応用ナイアシンアミドの皮膚での新しい作用と化粧品への応用. フレグランスジャーナル 32 (2) : 35-39, 2004.
11) 森貞夫, 高垣欣也, 中山樹一郎 : フラバンジェノールの美白・美肌作用. Food style 21 8 (6) : 38-40, 2004.
12) 倉橋敦, 小黒芳史 : 麹甘酒に含まれる成分について. 日本醸造協会誌 112 (10) : 668-674, 2017.
13) 棟方明博 : 肌色の見えから顔色の見えへの昇華. 日本香粧品学会誌 40 (3) : 174-178, 2016.
14) 正木仁 : 機能性化粧品の展望. 薬剤学 75 (5) : 313-316, 2015.
15) 中村睦子, 征也智美, 丹野修 : 官能特性用語「肌のなめらかさ」の解析~消費者意識・目視評価・皮膚整理パラメータ計測を用いて~. 日本化粧品技術者会誌 45 (4) : 306-314, 2011.
16) 田嶋和夫, 今井洋子 : 三相乳化法 : 通常の海面活性剤によらない乳化技術. 日本化粧品技術者会誌 50 (4) : 283-293, 2016.
17) 山下裕司 : 化粧品分野における界面活性剤の新展開. 色材協会誌 93 (3) : 84-90, 2020.
P.313 掲載の参考文献
1) 山田秀和 : 最近の女性に多いシワの種類に対する傾向と対策. COSMETIC CTAGE 12 (2) : 1-7, 2017.
2) 山崎律子 : 加齢による皮膚の変化とスキンケア. 繊維製品消費科学 55 (11) : 823-826, 2014.
3) 金辰也 :抗シワ化粧品の最新評価技術と製品開発. COSMETIC CTAGE 12 (2) : 8-13, 2017.
4) 日本香粧品学会編集事務局 : 抗シワ製品評価ガイドライン. 日本香粧品学会誌 30 (4) : 316-332, 2006.
5) 日本香粧品学会編集事務局 : <化粧品機能評価法ガイドライン> 新規効能取得のための医薬部外品美白機能評価試験ガイドライン. 日本香粧品学会誌 30 (4) : 333-337, 2006.
6) 高橋康之「保湿化粧品とその作用」. 日本香粧品学会誌 42 (4) : 280-287, 2018.
7) 早川淳一, 吉川麻美 : 美白評価技術とアンチエイジンク素材「枸杞 (クコ) 果実エキス」Food style 21 16 (5) : 92-94, 2012.
8) 柳井久江 : 4 Steps エクセル統計 第4版. オーエムエス出版, 東京, 2015.
9) 小出千春, 鈴木正, 水谷友紀, 他 : 日本人のしみ, そばかす, および美白化粧品等の実態に関するアンケート調査. 日本香粧品学会誌 30 (4) : 306-310, 2006.
10) 正木仁 : 機能性化粧品の展望 75 (5) : 313-316, 2015.
11) 岡野由利 : スキンケア化粧品のコンセプトの変化-角質を保湿することの重要性-. J Soc Cosmet Chem Jpn 50 (2) : 91-97, 2016.

最近チェックした商品履歴

Loading...